×

Alcobra Ltd. to Present at Upcoming Investment Conferences

TEL AVIV, Israel, March 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced corporate presentations at the upcoming 28th Annual ROTH Conference and the Barclays Global Healthcare Conference.

28th Annual ROTH Conference
Date:Monday, March 14
Time:1:00pm Pacific Time
Location:Ritz Carlton, Laguna Niguel, California
Presenter:David Baker, Chief Commercial Officer


Barclays Global Healthcare Conference
Date:Thursday, March 17
Time: 10:45am Eastern Time
Location:Loews Miami Beach Hotel, Miami, Florida
Presenter:Dr. Yaron Daniely, President & Chief Executive Officer
Webcast:https://cc.talkpoint.com/barc002/031516a_ae/?entity=72_U2Q8T5Q

About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com

Source:Alcobra Ltd.